LinkedIn Google+ Twitter Facebook

Caris Presents

Caris' scientific experts contribute to the advancement of science at various symposia and conferences worldwide. Please enjoy these featured presentations.

2015 Genitourinary Cancers Symposium (ASCO-GU)

A multiplatform biomarker analysis of small cell bladder cancers

Biomarker Patterns of Localized and Metastatic Prostate Cancer

Identification of actionable targets in chromophobe renal cell

Multiplatform molecular analysis of biomarkers in renal cell carcinoma

2015 Gastrointestinal Cancers Symposium (ASCO-GI)

Tumor profiling of biliary tract carcinomas reveals distinct molecular alterations and potential therapeutic targets

Molecularly-guided therapeutic options beyond TKIs for Gastrointestinal Stromal Tumors (GIST)

Comprehensive multiplatform biomarker analysis of 313 hepatocellular carcinoma identifies potential novel therapeutic options

Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas

2014 American Society of Clinical Oncology (ASCO) Annual Meeting

Results of comprehensive molecular profiling of gliomas and the potential therapeutic implications

Molecular profiling of testicular cancer

Programmed death 1 (PD-1) lymphocytes and ligand (PD-L1) in colorectal cancer and their relationship to microsatellite instability status

Molecular profiling of 6,892 colorectal cancer patients to identify potential treatment options

Molecular profiling of bile duct and gallbladder cancer to identify different therapeutic options

Profiling of 1,350 neuroendocrine tumors for identification of multiple potential drug targets

Potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), and mutational analysis

Multiplatform molecular profiling of 2,400 pancreatic adenocarcinomas to identify targets for therapeutic intent

Molecular profiling of small bowel adenocarcinomas

The impact of tumor molecular profile-directed treatment on survival in recurrent ovarian cancer

Molecular analysis of non-epithelial ovarian cancer by histologic subtype

Further molecular profiling of tumors harboring therapeutic targets within non-small cell lung cancer

Molecular profiling of non-small cell lung cancer by histologic subtype

Molecular profiling of HPV-positive and -negative HNSCC

Molecular abnormalities of 17 types of gastrointestinal cancer in an international cohort of 11,324 patients

Tumor profiling of 1,306 gastric and esophageal carcinomas and different treatment options

Molecular profiling of clear cell ovarian carcinoma

Molecular profiling of 267 pediatric cancers to identify potential clinically relevant targets

Genomic and protein alterations in 126 triple-negative (TN) metaplastic breast cancers

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Expression of novel immunotherapeutic targets in triple-negative breast cancer

2014 Genitourinary Cancers Symposium (ASCO-GU)

Molecular Profiling of Advanced Refractory Prostate Cancer

Molecular Profiling of Infiltrating Urothelial Carcinoma of the Bladder

2014 Gastrointestinal Cancers Symposium (ASCO-GI)

Profiling of 1,250 Neuroendocrine Tumors Identifies Multiple Potential Drug Targets

Molecular Profiling in Gastric Cancer: Examining Potential Targets for Chemotherapy

Prevalence of KRAS, BRAF, NRAS, PIK3CA and PTEN alterations in colorectal cancer: analysis of a large international cohort of 7,186 patients

Potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC), fluorescent in situ hybridiza&on (FISH) and mutational analysis.

Read an Oncology Times article, featuring Caris’ Dr. Zoran Gatalica, about how tumor profiling is changing treatment approaches for CUP patients

2013 San Antonio Breast Cancer Symposium (SABCS)

Comparison of Mutations and Protein Expression in Potentially Actionable Targets in 5,500 Triple Negative vs. Non-Triple Negative Breast Cancers

Watch Caris’ Dr. Sheri Millis discuss how identifying genomic and proteomic alterations can help inform ongoing clinical trials in poor prognosis cancers

2013 Society for Neuro-Oncology (SNO) Conference

Differences in Biomarker Expression in GBM Patients with Early Progression After Surgery

Molecular Profiling of GBM Patients Developed Pseudoprogression After Chemoradiation Treatment

Read Dr. Ryan Bender's article in ADVANCE for Administrators for the Laboratory: Molecular Profiling For CUP Patients

2013 Association for Molecular Pathology (AMP)

Distribution of cMET by IHC, FISH, and Next Generation Sequencing in Cancer – A Large Cohort Analysis

ERBB2 (HER2) Mutation Spectrum in Solid Tumors

Ras-ERK and PI3k-mTOR Pathway Profiling in Solid Tumors and Implications for Clinical Oncology

Concordance Between PTEN Protein Expression and Gene Mutations in the Large Cohort of Cancer Patients

Practical Issues in Identifying and Communicating Incidental and Unexpected Findings Arising from Mutation Analysis Utilizing Next Generation Sequencing for Clinical Oncology

2013 European Cancer Congress (ECCO)

Molecular Profiling of Cancers of Unknown Primary Site (CUP): Paradigm Shift in Management of CUP

Watch Dr. Zoran Gatalica Discuss His ECCO Presentation on Cancer of Unknown Primary

2013 American Society of Clinical Oncology (ASCO) Annual Meeting

A Pilot Study Utilizing Molecular Profiling to Find Potential Targets and Select Individualized Treatments for Patients with Metastatic Breast Cancer

The objective of this prospective pilot study was to determine if treatment selected by molecular profiling (MP) of metastatic breast cancer (MBC) tumors at time of disease progression provides greater clinical benefit than empiric treatment selection. This study demonstrates the feasibility of a highly multiplexed genomic and proteomic MP study for treatment selection in a timely fashion. Patient-specific target driven treatment selection based on MP of a metastatic lesion provided clinical benefit for 10 of 25 heavily pretreated MBC pts.

Biomarker Analysis of Glioblastoma and Potential Implications for Therapy

Glioblastoma multiforme (GBM), the most aggressive CNS cancer, has limited e¬ffective therapeutic options, with underlying molecular heterogeneity contributing to the differences in treatment response. This study was designed to interrogate biomarkers from a large cohort of GBM patients to seek therapeutic implications. By profiling tumor biomarkers from a large cohort of GBM patients using validated assays in a single reference laboratory, the vast molecular heterogeneity of GBM was demonstrated and the importance of individualized therapy based on a patient’s unique tumor profile was highlighted. Incorporating a comprehensive biomarker analysis into clinical management of this aggressive cancer allows for an informed selection of more effective therapies.

2013 International Society for Extracellular Vesicles (ISEV)

Circulating Microvesicles Contain Critical Elements of the RISC Complex

Effect of Colonoscopy on Circulating Microvesicles

Identification and Implications of Transcription Factors in Circulating Microvesicles From Cancer Patients

Multicolor Flow Cytometric Analysis of Cancer-Derived Microvesicles Reveals a Unique Subpopulation Ratio in Plasma From Prostate Cancer Patients

View Dr. Ryan Bender's presentation from the 2013 ACMG Annual Clinical Genetics Meeting:Clinical Application of Next Generation Sequencing for Personalized Medicine in Solid Tumors

2013 Gastrointestinal Cancers Symposium (ASCO-GI)

Molecular profiling (MP)-selected therapy for the treatment of patients with advanced pancreaticobiliary cancer (PBC)

For patients (pts) with advanced PBC who are able to pursue additional therapy, treatment selection is often empiric and clinical benefits are usually modest. Our goal was to study clinical outcomes of MP-guided treatment in advanced PBC. This retrospective analysis included pts with advanced PBC whose tissue samples underwent MP (IHC, microarray [MA], and sequencing analyses) using Target Now (Caris Life Sciences, Irving, TX). These pts received ≥1 lines of therapy for advanced PBC before their treatment was guided by MP.

Check out recent presentations from the Caris Life Sciences® 2012 ASCO Symposium

The opinions expressed in these videos are the opinions of the speakers and do not necessarily reflect the viewpoints of Caris Life Sciences. Caris Life Sciences is not responsible for the accuracy of the content contained in these videos.

In Bring on the biomarkers, personalized medicine advocate and expert Dr. George Poste argues that the dismal patchwork of fragmented research on disease-associated biomarkers should be replaced by a coordinated “big science” approach. The article appears in the January 13, 2011, issue of Nature.

Read Dr. George Poste's keynote presentation at the Montreux Symposium on Personalized Medicine in Switzerland. The speech occurred on November 10, 2010, and covered the opportunities and challenges presented by the evolution of personalized medicine. Topics covered included:

  • New Value Propositions in Healthcare
  • Mapping Genetic Predisposition to Disease
  • The Progressive Evolution of Personalized Healthcare
  • Biomarkers, Biosignatures and Molecular Diagnostics: The Key Value Drivers for Personalized Medicine, Improved Healthcare and Maximizing Wellness
  • The Value of Blood-Based Diagnostic Profiling
  • Remote Health Status Monitoring
  • Biosignature Profiling ViaSensors and Devices
  • Genes and Intellectual Property
  • The High Information Content (Complexity) of Biological Datasets
  • Leveraging the Potential of Molecular Medicine

Download the keynote presentation from the Burrill Conference on Personalized Medicine presented on September 17, 2010, by Dr. George Poste. The presentation provided a broad perspective on the multiple dimensions of biomarker validation from specimen acquisition to reimbursement to the importance of social media in reaching patients.

Sustaining Healthcare Innovation in an Era of Constraint

Key points of the presentation included:

  • Major challenges in healthcare
  • New priorities in biomedical innovation
  • Optimizing the efficiency of healthcare delivery and maximizing wellness
  • Discovery, validation and qualification of biomarkers
  • The key strategic elements in the evolution of healthcare

Read and view a presentation from Dr. Jonathan Knowles, PhD. Dr. Knowles was a featured presenter, on behalf of the Finnish Institute of Molecular Medicine, at the second annual Worldwide Innovative Networking (WIN) Symposium in Paris, France.

Dr. Knowles' presentation addressed emerging research findings in the development of cancer testing technologies that have the potential to make a dramatic impact on the lives of patients. He delivered this talk on Thursday, July 8, 2010. The abridged transcript and PowerPoint presentation of the speech are available:

Download Dr. George Poste's presentation about challenges and opportunities in cancer detection and diagnosis. This presentation addressed:

  • The imperative to achieve earlier detection and diagnosis
  • The role of disease-associated biomarkers as drivers in the future healthcare value chain
  • The cancer biomarker challenge

This program was presented on May 21, 2010, at the National Cancer Institute.


David D. Halbert Chairman & CEO

Tour Our Laboratory

Our Locations

view map

6655 North MacArthur Blvd
Irving, TX 75039
Toll Free: 866.771.8946

view map

4610 South 44th Place
Phoenix, AZ 85040
Main: 602.464.7500

view map

4750 South 44th Place
Phoenix, AZ 85040
Main: 602.464.7500

view map

St. Jakobsstrasse 199
CH - 4052 Basel
Main: +41.21.533.53.00